|
|
July
26,
2008 -- 2:40pm EDT
CT in the OC and the DC
A good and balanced piece about CT angiography
(CTA) recently appeared not
in the New York Times, but in the Orange County
Register. Authored by Colin Stewart, who writes a regular column on
"Biomedical Innovation", the article is titled, "CT
scans save lives, might also cut costs and radiation exposure"
-- and the title kind of says it all.
He has quotes from several OC sources, including Doug
Ryan from CT manufacturer Toshiba (they're in Tustin, just down
the freeway). But Stewart discusses
the reality of the radiation situation and makes several good
points, especially in light of all the negatively-skewed press (wag
of finger) that CTA has recently gotten. We're also happy to see
he's placed a link to our
coverage as well (tip of
hat).
Across the continent in Bethesda (well, not precisely
DC, but close enough) the National Heart, Lung and
Blood Institute (NHLBI) of the NIH just
concluded a
two-day panel of "All-Stars", according to Shelley Wood of
the theheart.org, to discuss
the issues around cardiovascular imaging and diagnosis. Wood reports
that the panel leaders, Drs. Allen Taylor and Michael
Lauer, told her:
"...there was no squabbling among
participants at the meeting to mirror the
growing rift between imaging proponents and naysayers in the wider
cardiology community."
Perhaps this get-together represented a cooling-off period,
because last fall Dr. Lauer was a
very vocal naysayer at the annual
AHA meeting and expressed strong anti-CT comments. According
to this report, also from theheart.org, Lauer definitely squabbled,
denouncing CTA and calling for a moratorium:
"We have a technology with no evidence of benefit;
we have a technology with real concern for harm.... The time
has come for the leadership of the cardiovascular community to
have
the courage to stop this and to change the paradigm by
which imaging technologies are promoted."
So it will most interesting to see what Dr. Lauer et
al come up with after last week's NIH panel in the way of
official requests for studies or clinical trials.
|
|
|